文献速递间质性肺疾病

多基因风险评分与特发性肺纤维化诊断及结局的关联

Association of a polygenic risk score with diagnosis and outcomes in idiopathic pulmonary fibrosis.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01

本研究利用四个独立生物银行队列(MGBB、MCBB、Tapestry、UKBB)的真实世界电子健康记录数据,评估特发性肺纤维化(IPF)多基因风险评分(PRS)与IPF诊断及无肺移植生存的关联。荟萃分析显示,高风险PRS与IPF诊断风险升高相关(OR=2.88;95%CI,2.41-3.44),并与IPF患者死亡或肺移植复合终点风险升高相关(HR=1.23;95%CI,1.11-1.35)。结论提示PRS可在生物银行规模数据中识别IPF诊断及死亡风险较高的个体。

要点

  • 高风险PRS与IPF诊断风险升高相关,OR为2.88(95%CI 2.41-3.44)。
  • 高风险PRS与IPF患者死亡或肺移植复合终点风险升高相关,HR为1.23(95%CI 1.11-1.35)。
  • PRS在真实世界电子健康记录数据中可识别IPF高风险个体,但临床效用待验证。

核心结论

  • PRS可在生物银行规模数据中识别IPF诊断及死亡风险较高的个体,可能对临床决策有启示。

研究设计与样本

  • 观察性研究,纳入4个独立队列:MGBB(37 709人)、MCBB(44 195人)、Tapestry(43 202人)、UKBB(447 422人)。
  • 采用多变量逻辑回归和多变量Cox比例风险模型,调整年龄、性别和 ancestry 主成分。
  • 各队列结果进行固定效应和随机效应荟萃分析。

主要发现

  • MGBB、MCBB、Tapestry、UKBB分别有1015(2.7%)、2879(6.5%)、1310(3.0%)、2742(0.6%)名参与者诊断为IPF。
  • 荟萃分析显示,高风险PRS与IPF诊断相关(OR=2.88;95%CI,2.41-3.44),对比所有其他个体。
  • 高风险PRS与IPF诊断患者死亡或肺移植复合终点相关(HR=1.23;95%CI,1.11-1.35),对比所有其他个体。

临床怎么用

  • PRS或可用于生物银行规模数据中IPF高危个体的识别。
  • 临床决策中是否加入遗传信息仍需进一步研究评估。

局限性

  • 需进一步工作评估在临床环境中加入遗传信息的效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Idiopathic pulmonary fibrosis (IPF) is characterized by chronic progressive pulmonary fibrosis and high mortality. Genetic markers, summarized into a polygenic risk score (PRS), associate with IPF in well-phenotyped research cohorts. OBJECTIVES: To evaluate the performance of the PRS using real-world data from routinely captured electronic health care records. METHODS: We conducted an observational study evaluating the association of a PRS for IPF with electronic health care record diagnosis of IPF as well as lung transplant-free survival in 4 independent cohorts: the Mass General Brigham Biobank (MGBB), Mayo Clinic Biobank (MCBB), Mayo Clinic Tapestry Cohort (Tapestry), and U.K. Biobank (UKBB). We used multivariable logistic regression and multivariable Cox proportional hazards models adjusting for age, gender, and principal components of ancestry. The cohorts then underwent fixed and random effects meta-analysis. MEASUREMENTS AND MAIN RESULTS: Of 37 709, 44 195, 43 202, and 447 422 participants from MGBB, MCBB, Tapestry, and UKBB, respectively, 1015 (2.7%), 2879 (6.5%), 1310 (3.0%), and 2742 (0.6%) participants had an IPF diagnosis. Meta-analysis demonstrated a high-risk PRS associated with IPF diagnosis (odds ratio [OR] = 2.88; 95% CI, 2.41-3.44) compared to all other individuals. A high-risk PRS also associated with the composite endpoint of mortality or lung transplant among those with an IPF diagnosis (hazard ratio [HR] = 1.23; 95% CI, 1.11-1.35) compared to all other individuals. CONCLUSIONS: A PRS can identify those at risk for an IPF diagnosis and mortality in biobank-scale data, which may have implications for clinical decisions. Further work is necessary to evaluate the utility of adding genetics in clinical settings.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Kalra SS, Grilli CB, Coombes BJ, et al. Association of a polygenic risk score with diagnosis and outcomes in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2026. PMID: 42391602. doi:10.1093/ajrccm/aamag271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。